10.25384/SAGE.9767369.v1 Luisa Guidi Luisa Guidi Daniela Pugliese Daniela Pugliese Tommaso Panici Tonucci Tommaso Panici Tonucci Lorenzo Bertani Lorenzo Bertani Francesco Costa Francesco Costa Giuseppe Privitera Giuseppe Privitera Barbara Tolusso Barbara Tolusso Clara Di Mario Clara Di Mario Eleonora Albano Eleonora Albano Gherardo Tapete Gherardo Tapete Elisa Gremese Elisa Gremese Alfredo Papa Alfredo Papa Antonio Gasbarrini Antonio Gasbarrini Gian Ludovico Rapaccini Gian Ludovico Rapaccini Alessandro Armuzzi Alessandro Armuzzi Supplemental Material2 - Supplemental material for Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease SAGE Journals 2019 Vedolizumab therapeutic drug monitoring Crohn’s disease ulcerative colitis 2019-09-04 12:08:15 Journal contribution https://sage.figshare.com/articles/journal_contribution/Supplemental_Material2_-_Supplemental_material_for_Early_vedolizumab_trough_levels_predict_treatment_persistence_over_the_first_year_in_inflammatory_bowel_disease/9767369 <p>Supplemental material, Supplemental Material2 for Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease by Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Barbara Tolusso, Clara Di Mario, Eleonora Albano, Gherardo Tapete, Elisa Gremese, Alfredo Papa, Antonio Gasbarrini, Gian Ludovico Rapaccini and Alessandro Armuzzi in United European Gastroenterology Journal</p>